6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study)

Article de revue

Avec comité de lecture

M. Ducreux, A. Adenis, J.P. Pignon, E. François, B. Chauffert, E. Boucher, M. Ychou, J.Y. Pierga, C. Montot-Grillot et T. Conroy

European journal of cancer supplements, Vol.7(2), pp.347-348

2009

Indicateurs

1 Consultations de la notice

Titre: 6084 Efficacy and safety of bevacizumab-based combination regimens in patients with metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab + FOLFIRI vs. bevacizumab + XELIRI (FNCLCC ACCORD 13/0503 study)
Créateurs - sans rôle: M. Ducreux
A. Adenis
J.P. Pignon
E. François
B. Chauffert
E. Boucher
M. Ychou
J.Y. Pierga
C. Montot-Grillot
T. Conroy
Détails de publication: European journal of cancer supplements, Vol.7(2), pp.347-348
Nombre de pages: 2
Identifiants: 99140064709311
Unité académique: Institut de Recherche en Cancérologie de Montpellier - IRCM
Langue: English
Type de ressource: Journal article